Linked Life Data

12029639

Source:http://linkedlifedata.com/resource/pubmed/id/12029639

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12029639rdf:typepubmed:Citationlld:pubmed
pubmed-article:12029639lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12029639lifeskim:mentionsumls-concept:C0019167lld:lifeskim
pubmed-article:12029639lifeskim:mentionsumls-concept:C0524909lld:lifeskim
pubmed-article:12029639lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:12029639lifeskim:mentionsumls-concept:C0205359lld:lifeskim
pubmed-article:12029639lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:12029639pubmed:issue6lld:pubmed
pubmed-article:12029639pubmed:dateCreated2002-5-24lld:pubmed
pubmed-article:12029639pubmed:abstractTextDuring the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) seroconversion to its antibody (anti-HBe) often coincides with normalization of liver biochemical test and clinical remission, but data regarding long-term outcome after spontaneous seroconversion are still scarce. Excluding patients with other virus(es) concurrent infection, 283 patients with chronic HBV infection were followed up for at least 1 year after spontaneous HBeAg seroconversion to anti-HBe. Follow-up studies included clinical, biochemical, and virologic evaluation and hepatocellular carcinoma (HCC) screening with ultrasonography and alpha-fetoprotein assay. During a median follow-up period of 8.6 years (range, 1 to 18.4 years) after HBeAg seroconversion in 283 patients, 189 (66.8%) showed sustained remission, whereas the remaining 94 (33.2%) experienced alanine aminotransferase (ALT) elevation over twice the upper limit of normal: 12 (4.2%) associated with HBeAg reversion, 68 (24%) with detectable serum HBV DNA but HBeAg negative, and 14 (4.9%) of undetermined causes. Of the 269 patients without evidence of cirrhosis at the time of HBeAg seroconversion, 21 (7.8%) developed cirrhosis with a cumulative incidence and relative risk significantly higher in patients developing active hepatitis than in patients with sustained remission (P <.05). HCC developed in 6 (2.2%) of the 283 patients, also with a significantly higher cumulative incidence in patients developing active hepatitis after HBeAg seroconversion (P <.005). In conclusion, the results suggest that spontaneous HBeAg seroconversion confers favorable long-term outcomes. However, active hepatitis still may develop and lead to cirrhosis and HCC.lld:pubmed
pubmed-article:12029639pubmed:languageenglld:pubmed
pubmed-article:12029639pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12029639pubmed:citationSubsetIMlld:pubmed
pubmed-article:12029639pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12029639pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12029639pubmed:statusMEDLINElld:pubmed
pubmed-article:12029639pubmed:monthJunlld:pubmed
pubmed-article:12029639pubmed:issn0270-9139lld:pubmed
pubmed-article:12029639pubmed:authorpubmed-author:ChuChia-MingC...lld:pubmed
pubmed-article:12029639pubmed:authorpubmed-author:YehChau-TingC...lld:pubmed
pubmed-article:12029639pubmed:authorpubmed-author:SheenI-ShyanI...lld:pubmed
pubmed-article:12029639pubmed:authorpubmed-author:LiawYun-FanYFlld:pubmed
pubmed-article:12029639pubmed:authorpubmed-author:ChiouHung-YiH...lld:pubmed
pubmed-article:12029639pubmed:authorpubmed-author:HsuYao-ShihYSlld:pubmed
pubmed-article:12029639pubmed:authorpubmed-author:ChienRong-Nan...lld:pubmed
pubmed-article:12029639pubmed:issnTypePrintlld:pubmed
pubmed-article:12029639pubmed:volume35lld:pubmed
pubmed-article:12029639pubmed:ownerNLMlld:pubmed
pubmed-article:12029639pubmed:authorsCompleteYlld:pubmed
pubmed-article:12029639pubmed:pagination1522-7lld:pubmed
pubmed-article:12029639pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:meshHeadingpubmed-meshheading:12029639...lld:pubmed
pubmed-article:12029639pubmed:year2002lld:pubmed
pubmed-article:12029639pubmed:articleTitleLong-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.lld:pubmed
pubmed-article:12029639pubmed:affiliationLiver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan.lld:pubmed
pubmed-article:12029639pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12029639pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12029639lld:pubmed